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Abstract- Hepatitis C Virus is one of the main reasons for chronic liver disease and hepatocellular 
carcinoma. Combination therapy with Interferon (peg-IFN-α) and Ribavirin (RBV) clear the virus more likely 
than the others. Different factors like virus and host characteristics influence on response to treatment. The 
most important viral factors include virus genotype and viral load; host factors like genetic, gender, race, age, 
weight and liver enzymes are also important. Previous studies have shown that single nucleotide 
polymorphisms (SNPs) in IFNR genes can regulate and influence on treatment with IFN. The purpose of this 
study is to investigate the association between SNPs in IFN-α receptor (IFNAR1 & IFNAR2) genes among 
subjects affected with chronic hepatitis C, who have treated with IFN and RBV, and also relationship 
between HCV genotypes and response to combination antiviral therapy. Peripheral blood mononuclear cells 
(PBMCs) were taken from whole blood of 61 patients affected with chronic hepatitis C who were treated with 
IFN and Ribavirin. Then, DNA was extracted from PBMCs and quality of DNA was assessed with Nanodrop 
finally two SNPs [Ex4-30G>C] and [Ivs1-4640 G>A] of IFN receptor genes (IFNAR1 and IFNAR2) were 
measured by TaqMan Real-Time PCR in ABi Prism 7900 system. Also to confirm the response rate to 
therapy, RNA was extracted then RT PCR was performed and final product was studied with gel 
electrophoresis and UV spectroscopy. Statistical analysis was performed using SPSS version 18.0 for 
Windows. The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-
30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 did not show any relationship with response to 
combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-α and 
Ribavirin. 61 patients complete the treatment period. 54 patients (%88/5) of them responded to treatment and 
7 patients (%11/5) did not. Research and data analysis have shown that there is no significant relationship 
between sex (P=0 /7) and age (P=0 /2). But there is a relationship between genotype-3a and response to 
combined therapy of IFN-α and RBV (0/02). Studies have shown that gene polymorphisms in IVSS1-22G 
location of IFNAR1 gene had a relationship with IFN treatment response. But current study has shown that 
there is no significant relationship between two SNPs Ex4-30G>C and Ivs1-4640 G>A and response to IFN 
therapy. In continue we suggest that it would be better to use this technique to evaluate other SNPs in IFN 
genes. 
© 2014 Tehran University of Medical Sciences. All rights reserved.  
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Introduction 
 
Hepatitis C virus (HCV) infection is one of the most 
serious problems in many parts of the world and a global 
public health problem with an estimated 170 million 
individuals chronically infected worldwide (1,2) . The 
center for disease control and prevention (CDC) 
reported that almost 1.8% of our population is anti-
HCV-Ab positive (3) the evidence show that HCV 
infection occurs in %1 of Iranian people (4). Most 
patient (75%) with HCV infection have chronic liver 
disease and show a wide range of signs and symptoms 
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(5,6). The chronic HCV is one of the major factors as 
the leading cause of increase in hepatic enzymes until 
the morbidity and mortality among liver cirrhosis, 
hepatic failure and hepatocellular carcinoma (HCC) in 
20-30% of infected persons (7,8). Hepatitis C is a highly 
contagious virus transmitted by intravenous drug abuse 
(9,10), sexual intercourse (11) and direct per- mucosal 
contact, vertical transmission (12), needle-stick injury, 
Health care exposure (blood transfusion, blood products 
and organ transplantation without HCV screening) and 
body piercings (13) but today, the most common and 
major cause for Acute HCV in more than %75 of new 
cases in Iranian people is drug injection (14).  
Interferon alpha is a major cytokine with 
characteristic of immune system stimulating and anti-
viral effects. In the past, INF-α was prescribed alone to 
prevention of liver disease progress (15) and its efficacy 
was confirmed by several clinical trial studies (16,17). 
Current studies show that combination therapy (anti-
viral drug ribavirin and peg-interferon alpha) causes an 
increase (40%) in stable response rate (18,19). Also the 
Pegylated INF-α has more molecular half life and less 
kidney clearance than INF-α and in combination with 
RBV cause a significant increase in sustained virologic 
response (SVR) (20).  
Ribavirin has some major properties in treatment 
such as direct inhibition of HCV proliferation, make a 
mutation in virus proliferation process and induce of 
increase in Th1 cells in immune system, but 
monotherapy by RBV cannot decrease the viral load in 
treatment duration (21-23).  
The genetic susceptibility, ethnic differences, 
environmental factors and virus factors such as virus 
load and virus genotype have influence on response or 
resistance to therapy with Interferon (24). In recent 
studies showed the kind of virus genotype has an 
important role in the response rate to the therapy; as a 
result, specifying that affects choosing the drug and 
usage duration (25). HCV has seven genotypes and 
major genotype is genotype 1 (40-80%) (26). The 
performed studies showed that sever liver disease and 
also HCC may be associated with genotype 1. 
According to the obtained documents, HCV genotype 1 
dose not respond to therapy as well as other genotypes 
(27-29).   
Host factors are other reasons of Hepatitis C virus 
resisting the therapy. There are several host factors that 
affect the response to interferon therapy. These factors 
include age, sex, race, obesity, and degree of hepatic 
fibrosis and duration of illness (30-32). On the other 
hand, everybody’s genetic factors have major roles in 
HCV infection risk and next immune responses. 
Several studies showed the probability of a positive 
relation between incidence of HCV disease and the 
host genetic polymorphism (Error!  Bookmark  not 
defined.).  
Some of these researches claim that some genetic 
polymorphism may affect on the process of HCV 
infection (33) and the response rate to current treatment 
(combination anti-viral drug ribavirin and peg-interferon 
alpha) is dependent on genotype differences (34-35). 
Many of biological and genetic factors can set the 
interferon alpha therapy. These factors are human 
leukocyte antigens (HLAs), cytokine polymorphism, and 
ethnicity (36-37). Some of the host MHC genes 
especially inflammatory cytokine genes have basic role 
for response to therapy (38). The type 1-alpha interferon 
receptors exist in most human cells and have at least two 
subgroups which are coded with IFNAR1 and IFNAR2 
genes that directly affect the signal transduction (39-41). 
Many of genes were identified by SNP analysis methods 
in disease, used for diagnostic methods as genetic 
markers (42-44). Investigations showed that single 
nucleotide polymorphisms (SNPs) of interferon receptor 
genes can set the alpha interferon therapy (45-46). 
Genetic tests have done on sequence of genes to predict 
the relation between polymorphisms and response to the 
therapy. 
 
Materials and Methods 
 
In this research, using molecular methods, SNPs in 
interferon receptor genes (IFNAR1, IFNAR2) in patients 
suffering from chronic Hepatitis C and also the 
relationship between them to response to combined 
therapy of interferon and ribavirin were investigated. 
 
Study population and Clinical characteristics 
The studied population in this research included 
patients suffering from chronic Hepatitis C who were 
recruited according to the documents of signs, 
symptoms, lab data (LFT) and imaging from Digestive 
Disease Research Institute, Tehran University of 
Medical Science. 72 patients who were infected by 
Hepatitis C virus were selected in zero time (before 
treatment). After we started the treatment, 11 patients 
refused to participate in the course of subsequent 
treatment and omitted from the list. So the genome of 
61 patients was studied. The study was approved by the 
Ethics Committee of Tehran University of Medical 
Science. Written informed consent was obtained from 
every selected subject.  
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Combination therapy 
The patients were treated by combination therapy 
with Pegylated-alpha interferon (Peg-IFNα) and 
Ribavirin (RBV: anti-viral drug). Peg-IFNα was injected 
subcutaneously once a week and the injected dose was 
180mg, and RBV capsules were prescribed daily 
according to the patient’s weight. For patients less than 
75kg, 1000mg capsules and for those more than 75kg, 
1200mg capsules were prescribed for a period of 24 
weeks.  
 
DNA extraction and TaqMan real time genotyping 
 Separation of Peripheral blood mononuclear cells 
(PBMCs) from whole blood of 61 patients who received 
Peg-IFNα and RBV was done. Then Genomic DNA was 
extracted and was purified from peripheral blood 
leukocytes using the QIAamp DNA Mini Kit (Qiagen). 
The kit was designed for rapid sedimentation of 
patients’ DNAs from biological liquids such as blood 
with high purity and exactly according to the kit leaflet. 
The procedures were performed with high speed and 
accuracy in a short time. All of the processes of nucleic 
acid extraction were done in RNAase and DNAase free 
condition. Nanodrop machine (N 1000, Thermo 
Company) was used to assess the quality of DNA. Then 
Taq Man SNP genotyping test was performed with Real-
Time PCR [ABi Real Time Prism 7900 (47,48)] for two 
SNPs: Ex 4-30GC and IVS1-4640GA related to 
interferon receptor genes (IFNAR1 and IFNAR2). 
Topologic and thermodynamic properties of primers 
were obtained and were confirmed with Gene Runner 
software. Final volume for one reaction in real-time 
PCR was 25µl, including TaqMan universal PCR Master 
Mix (12/5 µl), TaqMan Genotyping Assay Mix (0/75 
µl), DNA Template (8 µl) and DEPC (3/75 µl). The 
PCR protocol was as follows: 10 minutes at 95°C for 
initial step followed by 40 cycles of 15 seconds at 92°C 
(Denaturation) and 1 minute at 60°C 
(Annealing/Extension).  
 
RNA extraction and RT-PCR for confirmation of 
response to treatment 
The RNA extraction was performed by QIAamp 
viral RNA Mini Kit (Qiagen). Then with the use of one 
step RT-PCR Kit (Qiagen), reverse transcriptase 
reaction and PCR were done at the same time. Final 
products were loaded on 2% Agarose gel electrophoresis 
and were studied with UV spectroscopy.  
 
Statistical analysis 
Results were analyzed using SPSS software (version 
18, SPSS, Chicago, IL, USA). P value of <0.05 was 
considered as significant. Mean ± SD and relative 
frequency were used for quantitative and qualitative 
traits, respectively. SHAPIRO-WILK test was used to 
compare quantitative traits in subjects, before and after 
the treatment. Mean of quantitative traits in both groups 
was compared by t-test. The association of SNPs with 
the respond to therapy was tested using χ2 analysis. 
 
Results 
 
We conducted a case-control association study 
comprising 61 HCV-infected patients in two groups, 
before and after combination therapy to determine the 
relation between response to treatment and the kind of 
viral genotypes and IFNAR Gene SNP polymorphisms. 
The first results of PCR experiment were consisted 
of 20 patients, which are displayed in diagrams in figure 
2 which is included SNP proliferation diagrams and 
their proliferation to allele analysis. Every SNP has two 
alleles, IFNAR1 contains C and G alleles and the 
frequency of G allele is more than C and IFNAR2 has G 
and alleles that the frequency of G is more than A. To be 
more accurate, in this study, a negative control sample 
was evaluated for each SNP too. 
To determine the response to therapy, 61 plasma 
samples of patients were selected for this study and 
RNA was extracted exactly according to RNA kit with 
QIAam Viral RNA Mini Kit (Qiagen). Then with using 
One Step RT PCR kit both RT and PCR were 
performed with materials and schedule at the same 
time. After that, the final product of PCR was studied 
on %2 agarose gel with ultraviolet light. As it is 
obvious in figure 1, for example, it is specified that 
only three of 35 patients that PCR was done for their 
plasma samples (no. 6, 8, 26) were positive in the case 
of having HCV viral genome which shows that they 
are resistant to combined therapy of Interferon and 
Ribavirin, and there is no response to therapy. Samples 
of other patients (32 patients) were negative in the case 
of having HCV viral genome, which indicates that 
these patients have responded to the combination 
therapy of Interferon and Ribavirin (Table 1). 
Overally, in this research 72 patients with chronic 
Hepatitis C who received combination therapy of 
Interferon and Ribavirin were investigated and 11 of 
them did not take part in next treatments and were 
omitted from the research. Statistical analysis was 
performed on 61 patients. As mentioned in table1, 49 of 
them were men (%80.32) and 12 of them were women 
Z. Heidari, et al. 
    Acta Medica Iranica, Vol. 52, No. 10 (2014)    743 
(%19.67). The patients had a range of 22 to 65 years old, 
and average was 41.45 years. Their weight average was 
77.40kg. Among these 61 patients, 29 of them had 
genotype-1a (%47.5), 27 of them had genotype-3a 
(%44.3) and 5 of them had genotype-1b (%8.2) of 
Hepatitis C Virus, those 22 patients who had genotype-
1a and all individuals who had genotype-1b and 
genotype-3a responded to the treatment.  
 
 
Figure 1. Patients’samples no.1 to 35- positive control no.36 –ladder no.37 
 
Table 1. Data of 61 patients suffering from chronic Hepatitis C 
SNP2 SNP1 Response to therapy 
HCV 
Genotype A
G
E
 
SE
X
 
N
O
 
SNP2 SNP1 Response to therapy 
HCV 
Genotype A
G
E
 
SE
X
 
N
O
 
NS NS Neg 3a 49 M 32 Hetero Hetero Pos 1a 44 M 1 
Homo Hetero Pos 1a 51 M 33 Homo Hetero Neg 1b 52 M 2 
Hetero Hetero Neg 3a 25 M 34 Homo Hetero Neg 3a 36 M 3 
Homo Homo Neg 1a 58 M 35 Homo Homo Neg 1a 57 M 4 
NS NS Neg 1b 56 F 36 Hetero Hetero Neg 3a 57 F 5 
Hetero Hetero Neg 1a 57 F 37 Homo Homo Neg 3a 40 M 6 
Hetero Hetero Neg 3a 43 M 38 NS NS Neg 1a 50 M 7 
NS NS Neg 3a 65 F 39 Homo Hetero Neg 3a 30 M 8 
Homo Hetero Neg 1a 37 M 40 Homo Hetero Neg 3a 26 M 9 
Hetero Hetero Neg 3a 33 F 41 Hetero NS Neg 1a 40 F 10 
Hetero Hetero Neg 1a 52 M 42 Homo Hetero Neg 1a 31 M 11 
Hetero Hetero Neg 1a 47 F 43 Hetero Hetero Pos 1a 42 F 12 
Hetero Hetero Neg 3a 44 F 44 Homo Hetero Neg 1a 32 M 13 
Homo Hetero Neg 1b 24 M 45 Hetero Hetero Neg 3a 61 M 14 
Homo Hetero Neg 1a 34 M 46 Homo Homo Neg 1a 32 M 15 
Homo Homo Neg 1a 48 M 47 NS NS Neg 1a 34 M 16 
Homo Hetero Neg 3a 39 M 48 Homo Homo Neg 1a 46 M 17 
Hetero Hetero Neg 3a 22 M 49 Homo Hetero Neg 1a 29 M 18 
Hetero Hetero Neg 3a 40 M 50 Homo Hetero Neg 3a 35 M 19 
Homo Homo Neg 3a 30 M 51 Hetero Hetero Neg 3a 34 M 20 
Homo Hetero Neg 1a 40 M 52 Homo Homo Pos 1a 56 M 21 
NS NS Neg 3a 32 M 53 Hetero Hetero Neg 3a 35 M 22 
Homo Hetero Pos 1a 33 M 54 Hetero Hetero Neg 1a 27 F 23 
Hetero Hetero Neg 1a 31 M 55 NS NS Neg 3a 38 F 24 
Hetero Hetero Pos 1a 42 M 56 Homo Homo Neg 3a 43 M 25 
Homo Homo Neg 3a 35 M 57 Homo Hetero Neg 1a 36 M 26 
Homo Hetero Pos 1a 60 M 58 Homo Hetero Neg 3a 31 M 27 
Homo Hetero Neg 1b 65 F 59 Homo Hetero Neg 3a 31 M 28 
NS NS Neg 1a 50 M 60 Homo Homo Neg 3a 39 M 29 
Homo Hetero Neg 3a 57 M 61 Hetero Hetero Neg 1a 32 M 30 
       Homo Hetero Neg 1b 52 M 31 
NS: No SNP   
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Figure2. Two first diagrams are the results of SNPs proliferations and two others are the results of 
their proliferation with allele’s analysis 
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54 of the patients (%88.5) responded to the therapy 
and 7(%11.5) of them did not. Then using SPSS 
software, single nucleotide polymorphism Ex4-30GC in 
IFNAR1 gene and IVS1-4640GA in IFNAR2 gene and 
the relation between response to Interferon combination 
therapy and Ribavirin in chronic Hepatitis C patients 
was investigated. According to the results, there was no 
significant relation between investigated polymorphisms 
and response to the combined therapy (p=0.7). The 
number and percentage of homozygote and heterozygote 
SNPs among patients were shown in table 2.  
 
Table 2. Number of homozygote and 
heterozygote percentage of patients in SNPs
Homozygous 11(%18) 33(%54/1) 
Heterozygous 41(%67/2) 20(%32/8) 
No SNP 9(%14/8) 8(%13/1) 
 
In this study the relation between HCV genotypes, 
sex, and age of patients with their response to the 
Interferon combined therapy and Ribavirin was 
evaluated with using SPSS software. Investigation and 
analysis of the results have shown that there is no 
significant relation between sex (p=0.7), age (p=0.2) and 
the response to the therapy, but there is a significant 
relation between genotype-3a of virus and response to 
Interferon combined therapy and Ribavirin (p=0.02). 
That means patients who were infected by HCV 
genotype-3a respond better to the therapy than those that 
were infected by genotype-1a and genotype-1b.  
 
Discussion 
 
In this study, we aimed to explore the association of 
the polymorphisms of the Interferon receptor gene and 
HCV genotypes with the response rate to combination 
therapy in Chronic HCV infected Iranian population. 
Morgan et al., in 2008 studied the effect of 8 
polymorphisms among 638 patients with interferon 
therapy and showed that the gene polymorphisms were 
related to interferon treatment in IVSS1-22G of IFNAR1 
gene (Error! Bookmark not defined.).  
In another study they worked on 56 polymorphisms 
in 13 genes which were involved in interferon pathway 
and showed that the polymorphisms (IVS1-22G and 
Ex2-33 C) in IFNAR1 and IFNAR2 genes are associated 
with response to anti-viral therapy (49).  
Matsuyama et al. in 2003 showed a relation between 
a microsatellite in IFNR gene receptor and response to 
therapy (50).   
In this research we assumed that SNPs can cause 
changes in cellular immune response affecting the 
tending of receptors to alpha-interferon molecule, but 
the results showed that there is no significant relation 
between single nucleotide polymorphisms (Ex4-30 GC) 
and (IVS1-4640 GC) in IFNAR1 and response to 
combined therapy of Interferon and Ribavirin . 
We found a significant association between viral 
genotype-3a and response to combined therapy of 
Interferon and Ribavirin. This means that patients 
infected with HCV genotype-3a have better responded 
to therapy than those infected with genotype-1a and 
genotype-1b. We hope we could find patterns of 
resistant gene, as a result of our study, for better 
practical treatment strategy to cure the Iranian patients. 
In this study Genotyping has done by TaqMan PCR to 
find SNPs and Real Time PCR has done by ABi Prism 
7900 HT, which can analyze both color types, specify 
the color quantity and determine the genotypes for large 
number of samples in just few minutes (51). So we have 
suggested that studying of other SNPs in alpha 
interferon receptor (one SNP for IFNAR1 and four 
SNPs for IFNAR2) and their relation with response to 
Interferon and Ribavirin therapy is needed. 
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